<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811911</url>
  </required_header>
  <id_info>
    <org_study_id>498/12/20</org_study_id>
    <nct_id>NCT04811911</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum TWEAK Level in Psoriasis</brief_title>
  <official_title>Evaluation of the Effect of Narrowband Ultraviolet B Versus Methotrexate on Serum TWEAK Level in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the effect of NB-UVB versus MTX on serum TWEAK level in&#xD;
      psoriatic patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 13, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum TWEAK in psoriasis</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of tumor necrosis factor weak inducer of apoptosis (TWEAK) &quot;pg/ml&quot;; in psoriatic patients before and after treatment with NB-UVB versus MTX in comparison with healthy individuals, using ELISA (enzyme-linked immunosorbent assay).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment of psoriasis</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical evaluation: Assessment of disease severity will be performed by using psoriasis area severity index (PASI score) before and after treatment with NB-UVB in comparison with MTX. Patients will be photographed at baseline and after 3 months of regular treatment by using high resolution digital camera canon EOS 1300D 18 megapixels (made in taiwan), photography will be done in standard light and distance.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Narrowband ultraviolet B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 8 sessions of NB-UVB per month for 3 successive months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy individuals as control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Narrowband ultraviolet B</intervention_name>
    <description>Patients will receive 8 sessions of NB-UVB per month for 3 successive months</description>
    <arm_group_label>Narrowband ultraviolet B</arm_group_label>
    <other_name>NB-UVB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months</description>
    <arm_group_label>Methotrexate group</arm_group_label>
    <other_name>MTX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with moderate to severe plaque psoriasis of any age and gender.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of psoriasis treatment with systemic and biological agents prior to the study&#xD;
             for at least 3 months.&#xD;
&#xD;
          -  Pregnancy and lactation.&#xD;
&#xD;
          -  Infections&#xD;
&#xD;
          -  Patients with chronic diseases: hepatic disorders, hematologic disease, chronic renal&#xD;
             failure or cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moustafa A El Taieb, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of medicine aswan university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aswan University - Faculty of Medicine</name>
      <address>
        <city>Aswan</city>
        <state>Aswan Governorate</state>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 20, 2021</last_update_submitted>
  <last_update_submitted_qc>March 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>El Hassan Mohsen Mansour Mahmoud</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

